Eli Samaha Sells 25,027 Shares of Theravance Biopharma (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) major shareholder Eli Samaha sold 25,027 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $17.13, for a total value of $428,712.51. Following the transaction, the insider directly owned 9,212,252 shares of the company’s stock, valued at approximately $157,805,876.76. This represents a 0.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Eli Samaha also recently made the following trade(s):

• On Wednesday, July 1st, Eli Samaha sold 37,799 shares of Theravance Biopharma stock. The shares were sold at an average price of $17.00, for a total value of $642,583.00.
• On Monday, June 29th, Eli Samaha sold 273,871 shares of Theravance Biopharma stock. The stock was sold at an average price of $17.23, for a total value of $4,718,797.33.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH opened at $16.93 on Friday. The stock’s 50-day simple moving average is $16.57 and its 200-day simple moving average is $17.28. The firm has a market capitalization of $872.74 million, a PE ratio of 7.70 and a beta of 0.17. Theravance Biopharma, Inc. has a fifty-two week low of $10.82 and a fifty-two week high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The business had revenue of $17.70 million during the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. On average, sell-side analysts forecast that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TBPH has been the topic of a number of recent analyst reports. JonesTrading downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday. TD Cowen boosted their price target on shares of Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a research report on Monday, March 23rd. B. Riley Financial upped their price objective on shares of Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a research note on Tuesday, April 7th. Zacks Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, June 8th. Finally, Weiss Ratings cut Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 27th. One analyst has rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $21.40.

Hedge Funds Weigh In On Theravance Biopharma

Hedge funds have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Theravance Biopharma during the third quarter worth about $10,611,000. Pacer Advisors Inc. purchased a new position in shares of Theravance Biopharma during the fourth quarter worth about $6,342,000. Janus Henderson Group PLC increased its position in Theravance Biopharma by 214.8% in the 4th quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock valued at $7,493,000 after acquiring an additional 273,288 shares during the period. Two Sigma Investments LP increased its position in Theravance Biopharma by 1,199.9% in the 3rd quarter. Two Sigma Investments LP now owns 231,272 shares of the biopharmaceutical company’s stock valued at $3,377,000 after acquiring an additional 213,480 shares during the period. Finally, HRT Financial LP raised its stake in Theravance Biopharma by 892.8% during the 4th quarter. HRT Financial LP now owns 232,852 shares of the biopharmaceutical company’s stock valued at $4,356,000 after acquiring an additional 209,397 shares during the last quarter. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.